Cardiff Oncology (NASDAQ:CRDF) Coverage Initiated by Analysts at Craig Hallum

Analysts at Craig Hallum assumed coverage on shares of Cardiff Oncology (NASDAQ:CRDF) in a research report issued to clients and investors on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Craig Hallum’s price objective suggests a potential upside of 261.99% from the company’s current price.

Cardiff Oncology Stock Performance

Shares of CRDF opened at $2.21 on Friday. The business’s 50-day moving average is $2.30 and its two-hundred day moving average is $3.27. The company has a market capitalization of $102.88 million, a P/E ratio of -2.46 and a beta of 1.95. Cardiff Oncology has a fifty-two week low of $0.94 and a fifty-two week high of $6.42.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.12 million. During the same period last year, the business earned ($0.25) earnings per share. Analysts forecast that Cardiff Oncology will post -1 EPS for the current year.

Institutional Trading of Cardiff Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRDF. Assenagon Asset Management S.A. purchased a new stake in shares of Cardiff Oncology during the 1st quarter worth about $1,351,000. Callan Capital LLC grew its holdings in Cardiff Oncology by 37.2% in the first quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock valued at $228,000 after purchasing an additional 11,600 shares during the period. Blair William & Co. IL increased its position in shares of Cardiff Oncology by 32.4% in the first quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock valued at $919,000 after buying an additional 42,180 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Cardiff Oncology by 0.5% in the first quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock valued at $10,260,000 after buying an additional 9,468 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Cardiff Oncology in the second quarter valued at approximately $256,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.